JOURNAL ARTICLE

Research Data from Alexandria University Update Understanding of Schizophrenia (Comparing the Metabolic, Systemic, and Neuropsychiatric Impacts of Olanzapine and Clozapine in Patients with Schizophrenia).

  • Published In: Mental Health Weekly Digest, 2025. P. 1818 1 of 2

  • Database: Psychology Source 2 of 2

Abstract

The article focuses on a study comparing the effects of two atypical antipsychotics, Clozapine (CLZ) and Olanzapine (OLZ), on patients with schizophrenia. Conducted in Alexandria, Egypt, the research involved 48 patients and 24 healthy individuals over six months, assessing various metabolic, cardiovascular, inflammatory, and neurotransmitter parameters. The findings indicated that while both medications increased body weight and lipid profiles, CLZ had a more significant impact on metabolic parameters and therapeutic efficacy in reducing symptoms, whereas OLZ exhibited more pronounced anti-inflammatory effects. The study aims to inform treatment decisions for individuals with schizophrenia. [Extracted from the article]

Additional Information

  • Source:Mental Health Weekly Digest. 2025/10, p1818
  • Document Type:Article
  • Subject Area:Health and Medicine
  • Publication Date:2025
  • ISSN:1543-6616
  • Accession Number:188417027
  • Copyright Statement:Copyright of Mental Health Weekly Digest is the property of NewsRx and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.